The Children's Hospital of Philadelphia

Drexel University

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Ivan Alferiev

Robert J Levy

Michael Chorny

Ilia Fishbein

Darryl Williams

Stanley Stachelek

Garrett M Brodeur

Benjamin B Yellen

Boris Polyak

Gennady Friedman

Narendra Vyavahare

Zachary G Forbes

Kenneth A Barbee

Gershon Golomb

Gordon L Amidon

Eli Breuer

Naama El-Hanany Rozen

Aviva Friedman-Ezra

Jeanne M Connolly

Abigail Christian

Cunxian Song

Ilia Fischbein

Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.

Polymer-based macromolecular prodrugs

A co-drug according to Formula (I) or Formula (II) is provided,R&#x2014;X&#x2014;NH&#x2014;CO&#x2014;CO&#x2014;OR&#x2003;&#x2003;(I)R&#x2014;X&#x2014;CO&#x2014;O&#x2014;CH&#x2014;CO&#x2014;OR&#x2003;&#x2003;(II)wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and ORis the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO&#x2014;ORester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.

Cleavable esters for nanocarrier-based cancer therapy

Oxidation resistant bioprosthetic tissues and oxidation resistant bioprosthetic heart valve leaflets are described. Also provided are methods for preparing the oxidation resistant bioprosthetic tissues and bioprosthetic heart valve leaflets, and methods for preventing oxidative degeneration in bioprosthetic tissues, including immobilizing covalently an effective amount of an antioxidant to the bioprosthetic tissue.

Oxidation resistant bioprosthetic tissues and preparation thereof

A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.

Photochemical activation of surfaces for attaching biomaterial

A prodrug according to formula (I) wherein Ris a residue of a drug, said drug having a hydroxyl group by which the COORgroup is formed; Z is O or NH; m is 0 or 1; and Ris an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.

Hydrolytically releasable prodrugs for sustained release nanoparticle formulations

Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.

Uniform field magnetization and targeting of therapeutic formulations

A polymer is provided according to structure I wherein Y is a thiol-reactive group and Z is an ionogenic group. The surface of a polymeric substrate is modified by contacting the surface with a polymer according to structure II or structure III and exposing the surface to ultraviolet light, optionally followed by contacting the modified surface with the polymer according to structure I. 

Photo-activated attachment of cholesterol to polyurethane surfaces for adhesion of endothelial cells

A method and a composition for delivery of a biomaterial to an animal cell or a tissue, the composition includes (a) a biomaterial; (b) a biodegradable cross-linker portion having a hydrolyzable bond, wherein the biodegradable cross-linker portion is covalently bound to the biomaterial; and (c) a substrate, wherein the substrate is covalently bound to the biodegradable cross-linker portion, provided that the biodegradable cross-linker is adapted to hydrolyze by breaking the hydrolyzable bond and thereby release and deliver the biomaterial. A process of making the composition is also provided.

Biodegradable linkers for molecular therapies

A modified polyurethane including a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane, methods of preparing modified polyurethanes and the use thereof as an implantable biomaterial.

Steroid lipid-modified polyurethane as an implantable biomaterial, the preparation and uses thereof

A modified polyurethane including a lipid substituent from at least one urethane nitrogen and/or at least carbon atom of the modified polyurethane.

Growing community of inventors

Clementon, NJ, United States of America

Ivan Alferiev